This is a non-patent form of market exclusivity that effectively
prevents generic competition during the data protection period.
Not exact matches
The move may inhibit
competition by
preventing generic drug - makers from obtaining access to samples, Stock said.
Patent holders previously made such claims in order to delay the onset of
competition from
generic drug manufacturers, by
preventing or delaying FDA approval of a
generic manufacturer's Abbreviated New Drug Application (ANDA).